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Unlike epigenetic silencing of tumor suppressor genes, the role of
epigenetic derepression of cancer-promoting genes or oncogenes
in carcinogenesis remains less well understood. The tight junction
proteins claudin-3 and claudin-4 are frequently overexpressed in
ovarian cancer and their overexpression was previously reported
to promote the migration and invasion of ovarian epithelial cells.
Here, we show that the expression of claudin-3 and claudin-4 is
repressed in ovarian epithelial cells in association with promoter
‘bivalent’ histone modiﬁcations, containing both the activating
trimethylated histone H3 lysine 4 (H3K4me3) mark and the re-
pressive mark of trimethylated histone H3 lysine 27 (H3K27me3).
Duringovariantumorigenesis,derepressionofCLDN3andCLDN4
expression correlates with loss of H3K27me3 in addition to trime-
thylated histone H4 lysine 20 (H4K20me3), another repressive his-
tone modiﬁcation. Although CLDN4 repression was accompanied
by both DNA hypermethylation and repressive histone modiﬁca-
tions, DNA methylation was not required for CLDN3 repression in
immortalized ovarian epithelial cells. Moreover, activation of both
CLDN3 and CLDN4 in ovarian cancer cells was associated with
simultaneous changes in multiple histone modiﬁcations, whereas
H3K27me3 loss alone was insufﬁcient for their derepression.
CLDN4 repression was robustly reversed by combined treatment
targeting both DNA demethylation and histone acetylation. Our
study strongly suggests that in addition to the well-known chroma-
tin-associated silencing of tumor suppressor genes, epigenetic de-
repression by the conversely related loss of repressive chromatin
modiﬁcations also contributes to ovarian tumorigenesis via activa-
tion of cancer-promoting genes or candidate oncogenes.
Introduction
In addition to genetic DNA alterations, including mutations, deletions,
ampliﬁcations,rearrangementsandtranslocations,epigeneticabnormal-
ities are now known to be intimately involved in multistep carcinogen-
esis(1,2). The role of epigenetic silencing of key tumor suppressors by
DNA hypermethylation or histone modiﬁcations in their promoter re-
gions is now well established in tumorigenesis (2–4). Although
lesswellunderstood,thelossofepigeneticrepressionalsoplaysarolein
tumorigenesis, by facilitating the activation of oncogenes or cancer-
promoting genes, and global DNA hypomethylation at repetitive
sequences and imprinted genes also contributes to tumorigenesis by
promoting chromosomal instability or loss of imprinting (2,5,6).
Claudins are a 24-member family of proteins that are the major
components of tight junctions, epithelial cell–cell contacts that play
crucial roles in cell polarity maintenance and control of paracellular
ion ﬂux (7). Although loss of claudins has been associated with tu-
morigenesis (probably by allowing cell detachment and migration),
claudin-3 and claudin-4 have been demonstrated to be overexpressed
in several cancers including those of the breast, prostate and uterus
(7,8). More frequently, however, claudin-3 and claudin-4 have been
shown to be overexpressed in ovarian cancer (7–9), a malignancy that
is atypical in that it actually retains or gains (rather than loses) epi-
thelial characteristics during tumor progression (10,11). It is believed
thatclaudin-3andclaudin-4overexpressioninovariancancerenhances
tumor cell motility, invasiveness and survival, possibly by enhancing
proteolytic activation of basement membrane-degrading matrix metal-
loproteinases (12). Due to their consistent overexpression in ovarian
cancer andtheassociation ofclaudin-3 overexpressionwithpoor prog-
nosis, claudin-3 and claudin-4 are under investigation as diagnostic or
prognostic biomarkers (7,8). Furthermore, as claudins are transmem-
brane proteins with two extracellular loops, they represent promising
targets for therapeutic antibodies (7), and interestingly, claudin-3 and
claudin-4 are receptors for the Clostridium perfringens enterotoxin
(7,9,13), representinga possible targetedtherapeutic using C.perfringens
enterotoxin in ovarian cancer (7,9,13), whereas a CLDN3 small interfer-
ingRNA(siRNA)demonstratedpotentsuppressionoftumorgrowthand
metastasis of mouse and human ovarian tumor xenografts (14).
Despite the importance of the upregulation of claudin-3 and
claudin-4 in ovarian cancer, the mechanism by which their overex-
pression occurs remains under investigation, although recent studies
havesuggested the crucial roles of epigenetic modiﬁcations, including
DNA hypomethylation and histone H3 acetylation in the upregulation
of two genes in ovarian cancer cells (9,15,16). Interestingly, CLDN3
and CLDN4 are adjacent genes on chromosome 7q11.23, located only
 60 kb apart and being transcribed in opposite directions, suggesting
their possible coordinated regulation by sharing regulatory regions.
In addition to DNA methylation, the ‘histone code’ hypothesis pos-
its that covalent modiﬁcation of histone tail residues acts in concert to
govern DNA packaging and thus access of transcription machinery to
coding sequences (17,18). Histone modiﬁcations on speciﬁc residues
correlate with either active or repressive transcription (3,19). Specif-
ically, trimethylation of histone H3 lysine 9 (H3K9me3), H3 lysine27
(H3K27me3) and H4 lysine 20 (H4K20me3), facilitates transcrip-
tional repression, whereas histone acetylation of histone H3 (H3Ac)
and H4 (H4Ac), and trimethylation of H3 lysine 4 (H3K4me3) are
associated with active transcription (3,19). Methylation of speciﬁc
histone lysine residues is mediated by their cognate histone methyl-
transferases, and the recent discovery of histone lysine demethylases
has indicated that the ‘histone code’ is highly signal responsive and
dynamic (19,20). In embryonic stem cells, a ‘bivalent’ colocaliza-
tion of the activating H3K4me3 and the repressive H3K27me3 of
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H3K4me3 or H3K27me3, has been reported to allow differentiated
tissue silencing or expression (21,22). To ﬁne-tune gene regulation,
‘crosstalk’ between various epigenetic modiﬁcations has also been
reported (23–26). In particular, it is well known that histone
H3K9 methylation and H3K27me3 are linked to DNA methylation
(24,27–29).
In this study, we describe epigenetic mechanisms that regulate
CLDN3 and CLDN4 expression during ovarian tumorigenesis and
suggest that epigenetic derepression by loss of repressive histone
modiﬁcations is one possible mechanism underlying the overexpres-
sion of CLDN3 and CLDN4. These results demonstrate that DNA
methylation-independent epigenetic activation of previously re-
pressed cancer-promoting genes, in addition to the better understood
process of epigenetic silencing of tumor suppressor genes, may rep-
resent an additional mechanism of tumor progression.
Materials and methods
Cell lines and drug treatment
Human ovarian cancer cell lines were obtained from the American Type Culture
Collection (Manassas, VA) (Caov3, OV-90, SW626 and TOV-112D) or from the
KoreanCellLineBank(Seoul,Korea)(OVCAR3,SK-OV3,SNU8andSNU119).
Human immortalized ovarian surface epithelial (IOSE) cell lines were obtained
from Dr Nelly Auersperg (University of British Columbia, Vancouver, Canada)
(IOSE80UBC and IOSE385) and from Dr Michael Birrer (National Cancer In-
stitute, Bethesda, MD) (IOSE80NIH and IOSE120) and grown in 1:1 mixture of
Medium199andMCDB105supplementedwith5%fetalbovineserum.Primary
cultures of human normal ovarian surface epithelial (NOSE) cells were obtained
fromDrYong-SangSongoftheDepartmentofObstetricsandGynecology,Seoul
National University College of Medicine, following Institutional Review Board
approval, using resected healthy ovaries, followed by ovarian surface epithelium
exofoliation and culturing as described previously (30).
Cells were treated with 5 lM 3-deazaneplanocin A (DZNep; obtained from
Dr Victor E.Marquez of National Cancer Institute, MD) or 5 lM 5-aza-2’-de-
oxycytidine(5-aza-dC; Sigma,St. Louis,MO) for 72 h and 200 nM trichostatin
A (TSA; Sigma) for 24 h as described previously (31). Twenty micromolar
LY294002, a PI3K-Akt inhibitor (Sigma), was added to cells for 24 h (32).
Tissue samples and immunohistochemistry
Formalin-ﬁxed, parafﬁn-embedded (FFPE) tissues of human NOSE, ovarian
adenoma,borderline tumor and ovarian carcinoma which are de-identiﬁed and
anonymized, were obtained from the Samsung Medical Center (Seoul, Korea),
following approval by that institution’s review board. Immunohistochemistry
was performed as described previously (8) using Zymed antibodies against
EZH2 (36-6300), claudin-3, (18-7340) or claudin-4 (18-7341). We used the
same ovarian carcinoma FFPE tissues that were used for tissue microarray
analysis of the expression levels of claudin-3 and claudin-4 by Choi et al.
(8) for EZH2 immunohistochemistry.
Quantitative real-time reverse transcription–polymerase chain reaction
Total RNAwas extracted from cells using Trizol (Invitrogen, Carlsbad, CA) or
the Allprep (Qiagen GmbH, Hilden, Germany) kits and reverse transcribed to
complementary DNA using the SuperscriptTM II First-Strand Synthesis System
(Invitrogen) according to the manufacturer’s protocol. Following complemen-
tary DNA synthesis, quantitative polymerase chain reaction (PCR) was carried
out as described previously (33) in a dual system LightCycler (Roche Applied
Science, Mannheim, Germany) using the primers, Universal Probe Library
(Roche Applied Science) probe sequences are listed in supplementary Table S1
(available at Carcinogenesis Online), with the HPRT1 Taqman probe (TIB
MOLBIOL, Berlin, Germany) used as a ‘reference gene’ to normalize gene
expression.
Western blot analysis
Whole cell lysates were prepared by cell incubation with RIPA lysis buffer and
20–30 lg of total proteins were used for immunoblotting with antibodies to
claudin-3 (Zymed Laboratories, South San Francisco, CA; 18-7340), claudin-4
(Zymed, 18-7341), actin (Santa Cruz Biotechnology, Santa Cruz, CA;
sc-1616), H3K27me3 (Millipore, Temecula, CA; 07-449), EZH2 (Cell
signaling, Danvers, MA; 4905), SUZ12 (Abcam, Cambridge, UK; ab12073)
or EED (Millipore, 09-927).
Luciferase reporter assays
CLDN3 promoter luciferase reporter plasmids were constructed by PCR using
a bacterial artiﬁcial chromosome clone as a template (AC093168, RP11-
148M21/DH10B; Invitrogen) and the primers are listed in supplementary
Table S2 (available at Carcinogenesis Online). The PCR product was then
cloned into a pGL3-Basic (Promega, Madison, WI) and the correct product
conﬁrmed by DNA sequencing. Cells were harvested 16 h after cotransfection
with luciferase reporter and pCMV-lacZ plasmids using Lipofectamine LTX
(Invitrogen) according to the manufacturer’s instructions and ﬁreﬂy luciferase
activity was measured using a luciferase assay system (Promega). All experi-
ments were repeated three times.
Methylation-speciﬁc PCR and bisulﬁte sequencing PCR
CLDN3 and CLDN4 CpG islands were located using CpGIE (34) with the
following criteria: GC%  55; observed to expected ratio  0.65; length  500.
Genomic DNAwas extracted from (i) cells, using G-spin (iNtRON Biotechnol-
ogy, Seongnam-si, Korea) or Allprep (Qiagen) genomic DNA extraction kits or
(ii) ovarian FFPE tissues, using the ChargeSwitch gDNA Micro Tissue Kit
(Invitrogen) according to the manufacturer’s protocols. One microgram of ge-
nomic DNA was bisulﬁte modiﬁed using the EzWayTM DNA methylation De-
tection Express Kit (KOMABIOTECH, Seoul, Korea) and PCR ampliﬁed using
the primers and Taqman probes for methylation-speciﬁc PCR (MSP), quantita-
tive MSPandbisulﬁtesequencingPCRlistedinsupplementaryTablesS2andS3
(available at Carcinogenesis Online). For quantitative MSP, methylation levels
were calculated as percentage of methylated reference (%) by dividing CLDN3
orCLDN4:ACTB ratio ofa samplebythe CLDN3orCLDN4:ACTB ratioofSssI-
treated (and thus fully methylated) human leukocyte genomic DNA (from the
Samsung Medical Center) and multiplying this value by 100.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were performed using the EZ-
ChIP kit (Millipore) according to the manufacturer’s instructions with 5 lgo f
normal rabbit IgG (Cell signaling, 2729) as a negative control and 5 lg Milli-
pore antibodies against H3K4me3 (05-745), H3K27me3 (07-449), H3K9me2
(07-441), H3K9me3 (07-442), H3Ac (06-599), H4Ac (06-598), H4K20me3
(Abcam, 9053). ChIP primers and Taqman probes are shown in supplementary
Tables S2 and S3 (available at Carcinogenesis Online). Fold enrichment by
quantitative ChIP was calculated as the value of the immunoprecipitated
sample divided by the value of the negative control (IgG).
Transient siRNA transfection
Control (siGENOME, non-targeting siRNA #1) and gene-speciﬁc (EZH2,
SUZ12, On Target plus SMART pool) siRNAs were purchased from Dharma-
con (Lafayette, CO). After one or more siRNA transfections using Oligofect-
amine (Invitrogen), cells were harvested at various time points and used for
quantitative real-time reverse transcription–PCR, western blotting and ChIP
assays.
Establishment of stable cell lines
TOV-112D cells stably expressing H3K27me3 dominant-negative mutation
(TOV-K27R) or wild-type histone H3 (TOV-WtH3) were established through
G418 (Invitrogen) selection after transfection with the plasmids described pre-
viously (29). Transformants were ﬁrst selected by resistance to G418 (800 or
1000 lg/ml), and single-cell clones were then isolated by limiting dilution, with
plasmid stable expression conﬁrmed by enhanced green ﬂuorescent protein
ﬂuorescence.
Results
Repression of CLDN3 in ovarian surface epithelial cells is independent
of promoter DNA methylation
Using eight ovarian cancer and four IOSE cell lines, we ﬁrst con-
ﬁrmed a positive correlation between CLDN3 and CLDN4 messenger
RNA and protein levels, demonstrating both to be regulated at the
level of transcription (Figure 1A and B). Based on previous studies
suggesting the upregulation of CLDN3 and CLDN4 in ovarian cancer
cells via hypomethylation of promoter CpG islands (9,15,16), we next
performed MSP and quantitative MSP to further explore those pre-
vious correlations. MSP analyses of normal and malignant ovarian
cell lines demonstrated that CLDN4 messenger RNA levels inversely
correlate with CLDN4 promoter DNA methylation (Figure 1A), with
DNA hypermethylation in CLDN4-repressed IOSE cells being con-
sistent with the NOSE cells used by Litkouhi et al. (9). To further
conﬁrm CLDN4 methylation level, we performed bisulﬁte sequencing
PCR to quantitatively examine the methylation levels of individual
CpG dinucleotides. Bisulﬁte sequencing results were similar with the
MSP data, showing CLDN4 hypermethylation in CLDN4-repressed
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These ﬁndings conﬁrm that CLDN4 derepression in ovarian cancer
cell lines strongly associates with DNA hypomethylation, as
compared with its promoter hypermethylation-induced silencing in
primary NOSE or IOSE cells (Figure 1A).
However, unexpectedly, we observed little or no DNA methylation
in the CLDN3 promoter of six cell lines lacking CLDN3 expression
(OV-90, TOV-112D and four IOSE cells), in contrast to CLDN3 pro-
moter hypermethylation in SK-OV3 and SNU119 cells, two cell lines
that express CLDN3 at relatively low levels (Figure 1B). As shown in
Figure 1D, bisulﬁte sequencing PCR analysis also corroborated
the MSP data, further conﬁrming a lack of DNA methylation in
CLDN3-repressed cells, whereas CLDN3 expression (absent) and
DNA methylation levels (little or none) in primary cultured NOSE
Fig. 1. DNA methylation in the CLDN3 and CLDN4 promoters in ovarian cell lines and NOSE cells. (A) CLDN4 and (B) CLDN3 DNA methylation status by
MSP analysis in ovarian cell lines and NOSE cells. The location of CpG islands and regions for MSP and bisulﬁte sequencing PCR (BSP) are indicated in the
genomic sequence of CLDN3 and CLDN4 (top). The transcript and protein levels for CLDN3 and CLDN4 were measured by quantitative real-time reverse
transcription–PCR (qRT–PCR) and western blot, respectively (middle). The qRT–PCR values are represented as mean ± SD. DNA methylation status was
analyzed by MSP and quantitative MSP (qMSP) (bottom). Unmethylated (UM) and methylated (M) bands are shown and the quantitative methylation levels by
qMSP are represented as percentage of methylated reference (PMR, %). Human leukocytes (h.L), methylated in vitro by SssI treatment (h.L.M), were used as
a positive control. (C) CLDN4 and (D) CLDN3 DNA methylation status by bisulﬁte sequencing in ovarian cell lines. CpG sites analyzed by BSP in the CLDN4
(21 CpG sites) and CLDN3 promoter region (47 CpG sites) are indicated. At least 10 clones were sequenced and each row represents the methylation pattern of an
individual cloned PCR product (ﬁlled square, methylated CpG sites; open square, unmethylated CpG sites).
M.J.Kwon et al.
976cells were similar to IOSE cells. Taken together, our results demon-
strate a lack of DNA hypermethylation in the CLDN3 promoter region
in CLDN3-repressed cells, suggesting another mechanism(s) for gene
repression.
CLDN3 DNA methylation occurs in borderline tumors, whereas
CLDN4 is methylated in NOSE tissues
Based on different DNA methylation pattern between CLDN3-
repressed and CLDN4-repressed ovarian cells, we further compared
CLDN3 and CLDN4 promoter DNA methylation levels in FFPE sam-
ples from NOSE, ovarian adenoma, borderline tumors and ovarian
carcinomas. Similar to IOSE cells, CLDN3 was not methylated in
NOSE tissues (0%, 0/9), despite undetectable claudin-3 expression
in those normal tissues (Figure 2A; supplementary Table S4 is avail-
able at Carcinogenesis Online). Interestingly, in precancerous border-
line tumors, which had little or no claudin-3 expression (supplementary
Table S4 is available at Carcinogenesis Online), CLDN3 DNA promo-
ter methylation (62.5%, 5/8) was signiﬁcantly increased, as compared
with NOSE tissues (P 5 0.007) (Figure 2A). However, in ovarian car-
cinomas (26.8%, 15/56), CLDN3 methylation was signiﬁcantly lower
compared with that in borderline tumors (P 5 0.039) (Figure 2A;
supplementary Table S5 is availabe at Carcinogenesis Online). These
results suggest that CLDN3 promoter methylation increases during
ovarian premalignant tumorigenesis, but is lost in fully neoplastic
tumors, in agreement with a previous study (16).
In contrast to the lack of association between DNA methylation and
claudin-3 expression in premalignant tissues, the frequency and level
of CLDN3 methylation in the claudin-3-non-expressing group were
higher than in the claudin-3-expressing group (frequency: P 5 0.07;
level: P 5 0.077) in ovarian carcinomas (Figure 2B; supplementary
Table S5 is available at Carcinogenesis Online), demonstrating that
Fig. 2. DNA methylation status in the CLDN3 and CLDN4 promoters in ovarian FFPE tissues. (A) CLDN3 DNA methylation status in ovarian FFPE tissues.
Claudin-3 expression in ovarian tissues was examined by immunohistochemistry and expression levels were scored on a scale of 0–3 (upper panel).
Immunohistochemistry(IHC) 5 0 indicates negativeexpression and a value .0 was regarded as positiveexpression. The methylation level (y-axis) was calculated
as the mean percentage of methylated reference (PMR) value of two to six repeated quantitative MSP (qMSP) assays (lower panel). A PMR .0 was regarded as
methylated. A horizontal line within the box indicates the median value. Outliers and extremes are indicated as open circles in the box plots. Differences in
methylation levels between two groups of ovarian FFPE tissues were analyzed by the non-parametric Mann–Whitney test. A P-value , 0.05 (two-sided) was
regardedas statistically signiﬁcant.Statisticalanalyses were carriedoutusing SPSSVersion 12. (B) Relationship ofDNA methylationwithclaudin-3 expressionin
ovarian carcinoma tissues. The methylation level was also compared between claudin-3-expressing (IHC 5 1, 2, 3) and non-claudin-3-expressing tissues
(IHC 5 0) in ovarian carcinoma FFPE tissues. (C) CLDN4 DNA methylation status in ovarian FFPE tissues. Claudin-4 expression was determined by
immunohistochemistry (upper panel) and DNA methylation level by qMSP (lower panel).
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977CLDN3 promoter DNA methylation at least partially associates with
protein expression in ovarian carcinoma tissues.
We also examined CLDN4 promoter DNA methylation and protein
expression in normal and malignant ovarian FFPE tissues. Consistent
with the cell line data, CLDN4 methylation was frequently found in
NOSE tissues at frequencies and methylation levels similar to those
found in ovarian adenoma and borderline tumor tissues (Figure 2C;
supplementary Table S6 is available at Carcinogenesis Online). These
FFPE analyses indicate that in contrast to CLDN3, CLDN4 methyla-
tion is maintained during early-stage tumorigenesis. Interestingly,
there was no inverse correlation between claudin-4 expression and
DNA methylation in ovarian adenoma and borderline tumor tissues
(supplementary Table S4 is available at Carcinogenesis Online), de-
spite the strong inverse correlation observed in the cell lines studies
(Figure 1A), suggesting additional mechanisms of CLDN4 dysregula-
tion during premalignant tumor progression. In ovarian carcinomas,
CLDN4 was surprisingly methylated, with no signiﬁcant difference in
the levels and frequency of DNA methylation between the claudin-4-
expressingandclaudin-4-non-expressing groups(supplementary Table
S6 is available at Carcinogenesis Online). However, we note the small
number (n 5 7) of claudin-4-repressed carcinomas, in addition to
possible leukocyte contamination of the FFPE tissues, as CLDN4
was also found hypermethylated in human leukocytes (Figure 1A,
‘h.L’ bar).
To determine whether CLDN3 repression in IOSE cells and ovarian
cancer cell lines was due to absent transcription factors, we examined
luciferase reporter activity following deletion analysis of CLDN3 pro-
moter in four cell lines possessing varying levels of endogenous
CLDN3 expression. As shown in supplementary Figure S1 (available
at Carcinogenesis Online), luciferase activity of the various CLDN3
promoter fragments was similar among the four cell lines examined
(regardless of their CLDN3 expression status), in agreement with
a similar study of the CLDN3 promoter (16). These promoter regula-
tion studies conﬁrm that the basal transcription machinery remains
intact in both CLDN3-repressed and CLDN3-expressing cells, sup-
porting the role of other possible mechanism(s) of CLDN3 regulation
during ovarian tumorigenesis. Similarly with CLDN3, the same pat-
tern of luciferase activity of the CLDN4 promoter was also reported in
ovarian cancer cells regardless of their CLDN4 expression in previous
study (15).
Repression of CLDN3 and CLDN4 in IOSE cells is associated with
bivalent histone modiﬁcations, whereas their derepression in ovarian
cancer cells associated with loss of repressive H3K27me3 and
H4K20me3
To determine whether histone modiﬁcations in the CLDN3 promoter
mediate transcriptional repression, independently of DNA methyla-
tion, we performed ChIP studies of three distinct CLDN3 promoter
regions and quantitative ChIP of one region. Interestingly, the CLDN3
promoter showed a ‘bivalent’ colocalization of both repressive
H3K27me3 and activating H3K4me3 histone mark in CLDN3-
repressed IOSE cells in addition to CLDN3-repressed ovarian cancer
cell lines (OV-90 and TOV-112D), whereas H3K27me3 was lost in
CLDN3-expressing cells (Caov3 and SNU119) (Figure 3A). The most
disparately altered chromatin modiﬁcation between CLDN3-
repressed and CLDN3-expressing cells was the repressive
H3K27me3 histone mark, although loss of two other repressive
marks, H4K20me3 and H3K9me3, likewise associated with CLDN3
derepression, also independently of altered DNA methylation. Detect-
able H3K9me2 was not found in the CLDN3-repressed cells and
active chromatin marks, H3K4me3 and H3Ac, were observed in the
CLDN3 promoters of all cells, regardless of CLDN3 expression
(Figure 3A). In contrast to H3Ac, however, only low levels of
H4Ac were detected in the CLDN3 promoter of the three cell lines
(Caov3, SNU119 and IOSE80NIH) having varying levels of CLDN3
expression.
Similar to the CLDN3 promoter, we found a bivalent pattern of
CLDN4 promoter histone methylations in CLDN4-repressed IOSE
cells, which were DNA hypermethylated (Figure 3B). In addition to
DNA hypomethylation, loss of the repressive H3K27me3 and
H4K20me3 histone mark was observed in CLDN4-expressing cells
(SNU119 and Caov3), as compared with CLDN4-repressed cells. In
contrast to CLDN3, the CLDN4 promoter possessed detectable
H3K9me2, in addition to DNA hypermethylation, in cells lacking
its gene expression (TOV-112D and IOSE80NIH) (Figure 3B), sug-
gesting a link between these two repressive modiﬁcations in the
CLDN4 regulation, in accord with previous studies supporting such
an association (24,35). The levels of active histone mark H4Ac and
H3K4me3 were correlated with CLDN4 expression (Figure 3B),
whereas H3Ac levels were high regardless of CLDN4 expression
similar to CLDN3. These results indicate that in normal and malignant
ovarian epithelial cells, repressive histone methylations (H3K27me3,
H3K9me2 and H4K20me3) in the CLDN4 promoter, together with
DNA hypermethylation, strongly repress CLDN4, whereas activating
histone marks (H3K4me3 and H4Ac), in conjunction with DNA hy-
pomethylation, allow CLDN4 transcriptionally permissive.
CLDN3 and CLDN4 are not direct targets of EZH2 and loss of
H3K27me3 alone does not induce their derepression in ovarian cells
Trimethylation of H3K27 is catalyzed by the histone methyltransfer-
ase EZH2, a member of the Polycomb repressive complex-2 that is
also overexpressed in embryonic stem cells and in highly aggressive
epithelial malignancies (36). To examine the role of EZH2 in the
regulation of CLDN3 and CLDN4 expression, we utilized siRNA
transfection toknock downEZH2 in TOV-112Dcells, which normally
repress CLDN3 and CLDN4 in association with promoter H3K27me3.
Reduced levels of EZH2 messenger RNA and protein corresponded
with signiﬁcantly decreased H3K27me3 binding in both the CLDN3
and CLDN4 promoter region (P , 0.05) (Figure 4A).However, the loss
of these repressive chromatin marks did not correspondingly induce
CLDN3 or CLDN4 expression, as compared with the control siRNA
treatment (Figure 4A). Similar results were observed in CLDN3-a n d
CLDN4-repressed OV-90 cells (supplementary Figure S2 is available at
Carcinogenesis Online). Further attempts to augment EZH2 knock-
down by repeated EZH2 siRNA transfections or cotransfection of
EZH2 siRNA with an siRNA against SUZ12 in TOV-112D cells also
did not restore the expression of both genes (data not shown). We also
treated TOV-112D cells with the PI3K-Akt inhibitor LY294002 to in-
hibit EZH2 serine-21 phosphorylation and thus upregulate its H3K27
methyltransferase activity (32). This treatment actually increased
CLDN3 and CLDN4 expression (Figure 4B), rather than decreasing
the expression. Additional evidence against direct EZH2 regulation
of CLDN3 and CLDN4 expression was provided by a lack of correla-
tion between EZH2 and claudin-3/claudin-4 expression by immunohis-
tochemistry in ovarian carcinoma tissues (supplementary Figure S3 is
available at Carcinogenesis Online).
We also established stable cell lines with a dominant-negative his-
tone H3 lysine 27 mutation in TOV-112D cells (TOV-K27R) to rule
out the possibility of incomplete H3K27me3 by transient siRNA
transfection and the existence of other methyltransferases involved
in the methylation of H3K27. In agreement with our EZH2 knock-
down ﬁndings, the TOV-K27R cells did not derepress CLDN3 or
CLDN4, as compared with untransfected TOV-112D or TOV-WtH3
cells (Figure 4C). Overall, these results suggest that the expression of
CLDN3 and CLDN4 is not solely regulated by EZH2, or that
H3K27me3 loss alone is insufﬁcient to derepress their expression
consistent with ﬁndings in previous reports (37,38), and lend support
to the idea that additional mechanisms might be involved in their
regulation.
Increased histone acetylation and simultaneous loss of repressive
H3K27me3 and H4K20me3 result in increased expression of
CLDN3 and CLDN4 in ovarian cancer cells
Recently, DZNep was found to deplete components of the Polycomb
repressive complex-2 complex and inhibit histone methylations, in-
cluding H3K27me3 and H4K20me3, whereas it had little effect on the
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978levels of H3K9me3 or H3Ac (39). To test whether DZNep, alone or in
combination with another epigenetic modulator, could regulate
CLDN3 expression in cells lacking its expression (TOV-112D, OV-
90 and IOSE80NIH), we assessed CLDN3 transcript levels after
mono- or co-treatment with the histone deacetylase inhibitor, TSA.
By themselves, DZNep or TSA treatment alone only slightly induced
CLDN3 expression in each cell line (Figure 5A). However, we de-
tected a strong (3- to 5-fold) increase in CLDN3 expression in all
three cell lines following treatment with DZNep combined with
TSA (Figure 5A), suggesting possible crosstalk of histone methyla-
tions (H3K27me3 and/or H4K20me3) with histone acetylation.
Interestingly, 5-aza-dC treatment induced CLDN3 expression in
TOV-112D and IOSE80NIH cells with very low DNA methylation
in contrast to no induction in OV-90 cells having little DNA methyl-
ation (supplementary Figure S4 is available at Carcinogenesis
Online). However, it was difﬁcult to detect the concomitant DNA
demethylation at CLDN3 promoter in TOV-112D and IOSE80NIH
cells after 5-aza-dC treatment (data not shown), suggesting that in-
creased CLDN3 expression by 5-aza-dC might occur independently of
DNA demethylation.
To examine possible mechanisms of DZNep/TSA-mediated
CLDN3 upregulation, we assessed changes in histone
Fig. 3. Histone modiﬁcations in the CLDN3 and CLDN4 promoters in ovarian cancer cell lines. (A) Histone modiﬁcations in the CLDN3 and (B) CLDN4
promoters. Location of the regions analyzed by the ChIP assay is indicated (top). Three regions of CLDN3 (ChIP I to ChIP III) and two regions of CLDN4 (ChIP I
to ChIP II) were analyzed for histone modiﬁcations by ChIP assays (left). Quantitative enrichment of histone modiﬁcations in the CLDN3 and CLDN4 promoters
was also assessed by quantitative ChIP (qChIP) assays using Taqman probe (right). y-axis represents the fold enrichment relative to IgG control. Gene expression
levels of CLDN3 and CLDN4 in each cell line are indicated under the name of cell line.
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mediated gene induction in TOV-112D and OV-90 cells. Polycomb
repressive complex-2 proteins (EZH2, SUZ12 and EED) levels
were further depleted when DZNep/TSA cotreated, as compared
with DZNep alone (Figure 5B). As shown in Figure 5C, the com-
bined treatment signiﬁcantly reduced CLDN3 promoter-localized
H3K27me3 and H4K20me3 (P , 0.05), with a slight decrease in
H3K9me3, while concomitantly increasing the activating mark
H3Ac and H4Ac (P , 0.05) in TOV-112D cells. These results
demonstrate that in addition to loss of repressive histone methyl-
ations, histone acetylations on both H3 and H4 may also regulate
CLDN3 expression. In OV-90 cells, both H3K27me3 and
H4K20me3 were signiﬁcantly decreased (P , 0.05) without
a marked increase in histone acetylation (Figure 5C), suggesting
that a reduction in multiple repressive histone methylation modi-
ﬁcations alone can allow gene induction when high levels of active
marks are already present.
As CLDN4 was repressed with DNA hypermethylation in ovarian
cells (Figure 1A and C), in addition to H3K27me3 and histone acet-
ylation, we also assessed the effects of a DNA methylation inhibitor,
5-aza-dC (alone or in combinations with DZNep or TSA), on CLDN4
expression in promoter-hypermethylated TOV-112D cells. We found
that combined 5-aza-dC/TSA treatment resulted in robust CLDN4
induction ( 16-fold), with only minimal induction by 5-aza-dC
monotreatment (Figure 5D, top). DNA demethylation was observed
in 5-aza-dC-treated cells (Figure 5D, middle), indicating that in-
creased CLDN4 expression by 5-aza-dC/TSA treatment is related to
DNA demethylation. Fairly similar to CLDN3, CLDN4 was induced
nominally ( 3-fold) by DZNep/TSA, although that combination in-
duced simultaneously signiﬁcant decreases in repressive marks
(H3K27me3 and H4K20me3) and increases in active marks (H3Ac
and H4Ac) in the CLDN4 promoter (P , 0.05; Figure 5D, bottom).
Unlike CLDN3, marked increases in the H3Ac and H4Ac were ob-
served, with H4Ac increased greater (5.1-fold) than H3Ac (2.5-fold).
Fig. 4. Effectofthe lossofH3K27me3on CLDN3andCLDN4expressionin ovarian cancercells.(A) EffectofEZH2 knockdownby EZH2siRNAonCLDN3and
CLDN4 expression. Knockdown of EZH2 transcripts (EZH2 var1 and EZH2 var2) and the decrease in protein levels of H3K27me3 were assessed in TOV-112D
cells 72 h after siRNA treatment (100 nM). The effect of EZH2 knockdown on H3K27me3 enrichment in the CLDN3 and CLDN4 promoters was also evaluated
by quantitative ChIP in TOV-112D cells.  P , 0.05, Mann–Whitney test. CLDN3 and CLDN4 messenger RNA (mRNA) levels after EZH2 siRNA treatment were
compared with the levels after control siRNA treatment. (B) Effect of LY294002 on CLDN3 and CLDN4 expression. CLDN3 and CLDN4 expression levels
were determined by quantitative real-time reverse transcription–PCR (qRT–PCR) in TOV-112D cells after a 24 h treatment with 20 lM LY294002. (C) CLDN3
and CLDN4 expression in TOV-K27R cells. The level of H3K27me3 in TOV-112D, TOV-K27R and TOV-WtH3 cells was assessed by western blotting and
the mRNA levels of CLDN3 and CLDN4 were assessed by qRT–PCR.
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hypomethylation are required for maximal CLDN4 derepression. In-
terestingly, DZNep treatment of TOV-112D cells induced the loss of
DNA methylation with a concurrent increase in demethylation of the
promoter region of CLDN4 (Figure 5D, middle), suggesting an in-
teraction between DNA methylation and Polycomb group proteins
(PcG)-mediated histone methylation in the regulation of CLDN4 ex-
pression, in agreement with a previous report (27).
These results indicate that CLDN3 and CLDN4 repression can be
robustly reversed by simultaneous changes in multiple epigenetic
modiﬁcations using combined treatment targeting several chromatin
modiﬁcations.
Discussion
Several candidate oncogenes, including BORIS, SNGG, IGF2 and
tumor progression-associated CLDN4, have been shown to be induced
by the loss of promoter DNA methylation in ovarian and other cancers
(40). However, little is known about activation of tumorigenesis-
associated genes due to the loss of other repressive epigenetic marks,
including silencing histone methylations.
In the present study, we ﬁrst demonstrate that CLDN3 and CLDN4
overexpression in ovarian cancer cells is associated with decrease of
the repressive histone methylation marks H3K27me3 and H4K20me3
in their promoter regions. Interestingly, we found CLDN3 to be
Fig. 5. Effects of DZNep, 5-aza-dC and TSA treatment on CLDN3 and CLDN4 expression and epigenetic modiﬁcations in ovarian cell lines. (A) Changes in
CLDN3 expression in ovarian cells treated with 5 lM DZNep (D), 200 nM TSA (T) or combination of DZNep/TSA. CLDN3 induction by quantitative real-time
reverse transcription–PCR is represented as the fold change (y-axis), calculated relative to no treatment (NT). (B) Effect of pharmacological treatments on
Polycomb repressive complex-2 (EZH2, EED and SUZ12) protein levels. (C) ChIP analysis of the CLDN3 promoter in TOV-112D and OV-90 cells untreated or
treated with DZNep/TSA. Fold enrichment was measured by quantitative ChIP.  P , 0.05. (D) Effect of DZNep, 5-aza-dC and/or TSA on the expression,
methylation status and histone modiﬁcations of CLDN4 in TOV-112D cells. Changes in CLDN4 expression (top), DNA methylation (middle) and histone
modiﬁcations (bottom) after DZNep, TSA, 5-aza-dC (A, 5lM) or their combined treatments are represented, respectively.  P , 0.05.
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methylation. Promoter bivalency, simultaneously possessing activat-
ing (H3K4me3) and repressive (H3K27me3) histone mark, is found in
numerous development-related genes in embryonic and hematopoi-
etic stem cells (21,41). This histone pattern is associated with a low
level of gene expression, keeping genes poised for activation (21,41).
Similarly, we found that CLDN3 and CLDN4 repression is associated
with promoter bivalency, with their upregulation associated with loss
of H3K27me3 and H3K4me3 retention. It has been recently demon-
strated that a H3K27me3 demethylase UTX forms a complex with the
H3K4 trimethyltransferase MLL2 (42), suggesting counter-modulation
of these two opposing histone marks in the loss of bivalency during
gene upregulation (20,42,43), and further studies could investigate
a role for this complexin tumorigenesis-associated CLDN3 or CLDN4
reexpression.
As expected, in highly gene-repressed cells, we observed the pres-
ence of additional repressive histone marks, including H3K9me3,
H4K20me3 and hypoacetylated H4 in CLDN3-repressed cells and
H3K9me2, H4K20me3 and hypoacetylated H4 in CLDN4-repressed
cells, consistent with previous reports (44,45). Although CLDN3 was
repressed in IOSE cells by histone modiﬁcations alone, CLDN4 ad-
ditionally possessed DNA hypermethylation in CLDN4-repressed
IOSE cells and NOSE tissues, consistent with previous cell line stud-
ies (9,15), indicating a more pronounced gene-suppressive chromatin
environment for that gene.
Previous studies have linked bivalent chromatin pattern or
H3K27me3 to mark genes for subsequent DNA methylation
(28,46), and in CLDN4 promoter, we indeed observed the presence
of both repressive marks. Although CLDN3 possessed H3K27me3,
but not DNA methylation, we did observe CLDN3 DNA methylation
in premalignant borderline tumor tissues consistent with the histone
mark acting as an identiﬁer for subsequent DNA methylation. Simi-
larly, DNA methylation has been associated with both H3K9me2
and H3K9me3 (24); however, although DNA-methylated CLDN4-
repressed cells possessed both histone marks, DNA methylation-
independent CLDN3 repression associated with H3K9me3 alone,
suggesting that H3K9me2, rather than H3K9me3, is more likely to
be linked to DNA methylation.
In contrast to some genes whose expression was reactivated by
EZH2 siRNA alone (47,48) or in H3K27 dominant-negative mutant
cells (29), CLDN3 and CLDN4 expression was not induced by EZH2
knockdown or loss of H3K27me3, suggesting that CLDN3 and
CLDN4 are not direct targets of EZH2 and PcG-mediated
H3K27me3 depletion alone insufﬁcient to derepress their expression,
in agreement with previous studies (37,38). However, DZNep treat-
ment in combination with TSA resulted in considerable CLDN3
induction with changes in multiple histone modiﬁcations in the
CLDN3 promoter. These results indicate that simultaneous changes
in multiple epigenetic modiﬁcations are required for CLDN3 expres-
sion induction, in agreement with previous reports (31,38).
Moreover, in CLDN4-repressed cells with DNA hypermethylation,
5-aza-dC treatment strongly induced CLDN4 expression in combina-
tion with TSA ( 16-fold) or with DZNep ( 4-fold), whereas inhibi-
tion of DNA methyltransferases or DZNep alone resulted in only
minimal reexpression, indicating the need for loss or gain of other
chromatin marks in addition to DNA hypomethylation for CLDN4
strong reexpression.
Although it needs to be biochemically determined whether strong
synergy by DZNep/TSA for CLDN3 or 5-aza-dC/TSA for CLDN4 is
generated by direct interaction between epigenetic modiﬁcations, si-
multaneous changes in epigenetic marks by combined treatment in
our study reﬂect possible interplay between histone modiﬁcations in
the regulation of CLDN3 expression or link between histone modiﬁ-
cation and DNA methylation in the regulation of CLDN4 expression.
Further studies will be required to address mechanistically if CLDN3
and CLDN4 are regulated by multiple chromatin modiﬁcations via
their crosstalk.
Although previous studies (15,16) reported the similar epigenetic
mechanism regulating CLDN3 and CLDN4 expression in ovarian
cancer, our study shows that different epigenetic mechanism is in-
volved in the alteration of claudin-3 and claudin-4 expression during
ovarian tumor progression. This might be due to different chromatin-
binding proteins including transcriptional factors in their upstream
regulatory elements because transcription regulatory factors are in-
volved in recruiting multiple chromatin modifying proteins, which in
turn regulate epigenetic modiﬁcations in the promoter region (49).
These ﬁndings raise the possibility of more complex upstream mech-
anism regulating CLDN3 and CLDN4 and further allow different epi-
genetic strategy targeting claudin-3 or claudin-4 for cancer therapy.
Finally, our ﬁndings suggest that epigenetic therapies capable of
targeting multiple histone modiﬁcations in the promoter regions of
CLDN3 and CLDN4 may have the potential to treat ovarian cancer.
Since the overexpression of CLDN3 and CLDN4 is related to ovarian
malignancy, repression of these genes in ovarian cancer by an epige-
netic approach could be used for treatment of ovarian cancer. Con-
versely, as claudin-3 and claudin-4 have been demonstrated to be
receptors for the C.perfringens enterotoxin, it is possible that their
further epigenetic upregulation could enhance the sensitivity to that
compound, similar to currently studied methods of derepressing cell
surface antigens for immunotherapy (50,51).
In conclusion, we have elucidated the epigenetic mechanisms
underlying the overexpression of CLDN3 and CLDN4 in ovarian can-
cer. Although there exists a growing number of examples or DNA
hypomethylation-related induction of candidate oncogenes, we fur-
ther demonstrate the crucial importance of histone modiﬁcations in
tumorigenesis-associated gene activation and suggest the epigenetic
derepression by loss of repressive histone modiﬁcations as one pos-
sible mechanism underlying the overexpression of cancer-related
genes during ovarian tumorigenesis. Our study offers novel insight
into cancer epigenetics and the current understanding of ovarian
tumorigenesis, and further suggests novel epigenetic approaches that
could be used to target these proteins for ovarian cancer therapy.
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Supplementary Tables S1–S6 and Figures S1–S4 can be found at
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